Related Experiment Video
Updated: May 17, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma
David J Pinato1, Paul Nya, Rohini Sharma
1Department of Experimental Medicine, Imperial Center for Translational and Experimental Medicine, Imperial College London, London, UK.
Background:
The differential diagnosis between malignant mesothelioma (MM) and metastatic lung adenocarcinoma (MLA) often relies on immunohistochemical studies, with no individual immunomarker holding satisfactory discrimination ability.
Methods:
We investigated the diagnostic accuracy of CD24 immunoreactivity on 134 patients including 69 cases of MM and 65 MLA.
Results:
The expression of CD24 favoured MLA, with 57/65 cases showing positive cytoplasmic staining compared with 9/69 MM (p<0.001), whose immunopositivity pattern was prevalently membranous (7/9 cases).
Conclusions:
CD24 positivity can accurately discriminate MM from MLA. Prospective studies are warranted to clarify whether CD24 could integrate with other immunomarkers to facilitate the diagnosis of mesothelial malignancies.
